Latest Biological Patent NewsRSS

07:03 EST 18th November 2017 | BioPortfolio

Global Nylon 6 Market Data List by Segment 20152022 [Report Updated: 10112017] Prices from USD $800

SnapshotNylon 6, is a polymer developed by Paul Schlack at IG Farben to reproduce the properties of nylon 6.6 without violating the patent on its production. It was given the trademark Perlon? in 1952.This report covers Nylon 6 basic market data by segment:1 by Product2 by EndUser3 by Company4 by Region5 by Channel6 by PriceThis report can also be customized according to further requirements.

Biosimilar battles: J&J drops Remicade patent dispute against Samsung Bioepis

Janssen has withdrawn a lawsuit against Samsung Bioepis alleging infliximab manufacturing patent infringements after receiving process information from the Korean drugmaker.

Patent expirations promise opportunities for generics makers

David SalazarPatent expirations on branded drugs are the generics industry’s bread and butter — and the years to come hold a lot of promise. read more

Innovus Pharmaceuticals Strengthens Its Intellectual Property Portfolio with New Patent for Its Sensum+® Product in Mexico

Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the “Company”) (OTCQB Venture Market: INNV), an emerging over-the-counter (“OTC”) consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women...

ARCA Biopharma Announces Issuance of European Patent for Treating Cardiovascular Diseases and Conditions With a New Chemical Entity Utilizing Genetic Targeting

WESTMINSTER, Colo., Nov. 16, 2017 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced the European Patent Office’s issuance of a patent (EPO # 2515899) on methods of treating cardiovascular disease and conditions with a thiol-substi...

ADMA Biologics Further Enhances Intellectual Property Portfolio Through Newly Issued U.S. Patent for Immunotherapeutic Compositions

RAMSEY, N.J. and BOCA RATON, Fla., Nov. 15, 2017 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) is a vertically integrated biopharmaceutical and specialty immunoglobulin company that develops, manufactures and commercializes plasma-based biologics for the treatment of immune deficiencies and prevention of certain infectious diseases, announced today that the United States Patent and...

Neuronascent Granted Composition of Matter Patent in Europe for Oral Neuron Regenerative Technology

CLARKSVILLE, Md., Nov. 14, 2017 (GLOBE NEWSWIRE) -- Neuronascent, Inc. (, a biopharmaceutical company focused on oral therapeutics to promote neuron regeneration, today announced the European Patent Office has issued EU Patent No. 1937252, on  October 25th, 2017, with claims of compounds and compositions for stimulating neurogenesis and inhibiting neuronal degeneration. ...

Align Technology Files Six Patent Infringement Lawsuits Asserting 26 Patents Against 3Shape

SAN JOSE, CA--(Marketwired - November 14, 2017) - Align Technology, Inc. (NASDAQ: ALGN) today announced that it has filed six patent infringement lawsuits asserting 26 patents against 3Shape A/S, a Danish corporation, and a related U.S. corporate entity, asserting that 3Shape's Trios intraoral scanning system and Dental System software infringe Align patents. Align filed two Section 337 complain...

Brazil farmers group asks court to cancel Monsanto GMO soybean seed patent

Biolog granted patent on novel treatment for Clostridium difficile infection - seeks commercial partner

HAYWARD, Calif., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Biolog, Inc. announced today that it has been granted US Patent 9,662,372 describing a new potential approach for treating life-threatening infections by the colon residing bacterium, Clostridium difficile (recently renamed as Peptoclostridium difficile).  The patent describes the discovery by Biolog scientists that cationic compounds can ra...

How To Address Unique Challenges With Generics And Process Scale-Up

ArticleBiosimilar manufacturers are creating generic versions of biologics and beginning the process of filing for approval once they come off patent.

AstraZeneca Earnings Fall Amid Patent Protection Losses

NewsAstraZeneca has been dealing with the loss of exclusivity on previous moneymakers like the cholesterol treatment Crestor and schizophrenia treatment Seroquel XR.

Mitochon Pharmaceuticals Announces First Patent Allowance for Mitochondrial Targeted Therapies for Neurodegeneration

Mitochon Pharmaceuticals today announced that it was notified by the US Patent and Trade Mark Office of allowance on its first patent, US 15/002,531 “INDUCED EXPRESSION OF BRAIN DERIVED NEUROTROPHIC FACTOR (BDNF) FOR TREATMENT OF NEUROMUSCULAR, NEURODEGENERATIVE, AUTOIMMUNE, DEVELOPMENTAL AND/OR METABOLIC DISEASE”. This patent allowance

Caris Life Sciences Files Patent Infringement Suit vs. Foundation Medicine

Caris Life Sciences has sued Foundation Medicine in federal court, accusing the company of infringing on five Caris patents in the development of its cancer assays FoundationOne ® , FoundationACT ® , and FoundationOne ® Heme. “As a result of Defendant’s infringement and the threat of its continued infringement, Caris faces a substantial risk of irreparable harm,” Caris sta...

Noven Files Patent Infringement Lawsuit against Alvogen

Noven Pharmaceuticals, Inc. announced today that it has filed a lawsuit in the U.S. District Court of Delaware against Alvogen, Inc. and Alvogen Pine Brook, LLC. (collectively, “Alvogen”) for patent infringement. Alvogen is seeking approval to market and sell a generic version of Minivelle® (estradiol transdermal system) prior to the expirati...

A Provisional Patent Application for Use of Specific Cannabis Strain in Neuropathic Pain Filed With the US Patent Office

VANCOUVER, British Columbia, Nov. 07, 2017 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (Frankfurt:2VP), (“Veritas” or the “Company”) announces that its research arm, Cannevert Therapeutics Ltd. ("CTL") filed a provisional patent application to US Patent and Trademark Office (the “USPTO”) on September 13, 2017 for use of a specific cannabis strain in neuropathic p...

Hospira to pay Amgen US$70 million for epoetin alfa patent infringement

US-based injectables specialist Hospira has been ordered to pay Biotech giant Amgen US$70 million in damages regarding a patent on Amgen’s anaemia blockbuster Epogen (epoetin alfa).

Biotech Patent Applications May be Eligible to Receive Benefits From Ongoing USPTO Initiatives

A pair of ongoing USPTO initiatives, Patents for Humanity and Patents 4 Patients , offer incentives that certain biotechnology patent applications may be eligible for. Patents for Humanity is open to patents and applications that address humanitarian challenges, and recognizes the winners with publicity and expedited examination or appeal of any application in which the winner has an ownership int...

STAT Plus: Pharmalittle: Allergan CEO says Mohawk deal wasn’t ‘desperation’; pharma layoffs are rising

Allergan chief executive officer Brent Saunders says a deal to transfer Restasis patent rights to the Mohawk tribe "wasn't desperation, it was tenacity."

Patent Allowance Granted For Cannabinoid, API Delivery Platform

NewsLexaria Bioscience receives groundbreaking U.S. patent allowance for its DehydraTECH delivery of THC, NSAIDs, nicotine, and vitamins. The allowance for broad API applicability is significantly ahead of expectations, the company said.

Global and China Heart Defect Closure Devices Market Research by Company, Type Application 20132025 [Report Updated: 21102017] Prices from USD $2000

SummaryMarket Segment as follows:By Type ASD Closure Devices VSD Closure Devices PDA Closure Devices PFO Closure Devices LAA Closure DevicesBy Application Atrial Septal Defect ASD Ventricular Septal Defect VSD Patent Ductus Arteriosus PDA Patent Foramen Ovale PFO Left Atrial Appendage LAABy Company St. Jude Medical Occlutech W. L. Gore Associates Boston S...

STAT Plus: What payoff? Patent settlements between brand and generic drug makers are declining

In pay-to-delay deals, a brand-name drug maker may offer cash or something else of value, such as a deal not to sell its own ‘authorized’ generic version.

Court clears Teva’s application for generic Uceris in patent-infringement suit

Teva said that if it’s application is approved, its Uceris generic may be entitled to 180-day exclusivity, as it believes it was the first company to file for approval on the product.  read more

Court clears Teva’s application for generic Uceris in patent infringement suit

Teva said that if it’s application is approved, its Uceris generic may be entitled to 180-day exclusivity, as it believes it was the first company to file for approval on the product.  read more

EXAS Ups Outlook, NEOS Rejects PDLI Offer, Not Much To Smile About For CRY

Today's Daily Dose brings you news about CryoLife's Q3 results and downwardly revised revenue outlook; improved Q3 financial results of Exact Sciences; patent infringement litigation between Celgene and Lannett and rejection of PDL BioPharma's proposal by Neos.

Quick Search

review and buy Biological Patent market research data and corporate reports here